3Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease[J]. Urol Clin North Am, 2003,30 ( 4 ) : 843 - 852.
4Liungberg B, Hanbury DC, Kuezyk MA, et al. Guidelines on renal cell careinoma[J]. Eur Assoc Urol,2008,1 -26.
5Escudier B,Eisen T,Stadler WM,et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med,2007,356(2) :125-134.
6Wilhelm SM ,Carter C ,Tang L,et al. BAY 43 -9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res,2004,64(19) :7099 -7109.
7Kaelin WG Jr. The yon Hippel-Lindau tumor suppressor gene and kidney cancer[J]. Clin Cancer Res, 2004,10 ( 18Pt 2 ) : 6290s - 6295s.
8Costa LJ, Drabkin HA. Renal cell carcinoma:new developments in molecular biology and potential for targeted therapies [J]. Oncologist ,2007,12(12) :1404 - 1415.
2Tourani JM, Lucas V, Mayeur D, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma: results of a multieenter SCAPP1 trial. Ann Oneol, 1996, 7:525-528.
3Donskov F, yon der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol, 2006, 24 : 1997-2005.
5Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer, 1997, 80: 1198- 1220.
6Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125- 134.
7Motzer R J, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356 : 115-124.
8Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, 2000, 6 : S55-57.
9Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 1995, 13:688-696.
10Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous infusion aIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer, 2004, 90: 1156-1162.
